{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:31:37Z","timestamp":1788877897482,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K06608"],"award-info":[{"award-number":["21K06608"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["2021-2023"],"award-info":[{"award-number":["2021-2023"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jphs.2022.01.006","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T01:02:34Z","timestamp":1642035754000},"page":"315-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies"],"prefix":"10.1016","volume":"148","author":[{"given":"Tomoyoshi","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Domoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riki","family":"Kamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misato","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maho","family":"Tsubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Fujitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigekatsu","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nishibori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3163-807X","authenticated-orcid":false,"given":"Atsufumi","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2022.01.006_bib1","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jphs.2022.01.006_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20122904","article-title":"Chemokine signaling in chemotherapy-induced neuropathic pain","volume":"20","author":"Brandolini","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jphs.2022.01.006_bib3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/ijms22010367","article-title":"Role of HMGB1 in chemotherapy-induced peripheral neuropathy","volume":"22","author":"Sekiguchi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jphs.2022.01.006_bib4","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/bph.15091","article-title":"Role of high-mobility group box 1 and its modulation by thrombomodulin\/thrombin axis in neuropathic and inflammatory pain","volume":"178","author":"Tsujita","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jphs.2022.01.006_bib5","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1158\/0008-5472.CAN-20-2799","article-title":"Pronociceptive roles of Schwann cell-derived galectin-3 in taxane-induced peripheral neuropathy","volume":"81","author":"Koyanagi","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jphs.2022.01.006_bib6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s43440-020-00109-y","article-title":"Chemotherapy-induced peripheral neuropathy: part 1-current state of knowledge and perspectives for pharmacotherapy","volume":"72","author":"Salat","year":"2020","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.jphs.2022.01.006_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","article-title":"Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk","volume":"159","author":"Bao","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jphs.2022.01.006_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jphs.2021.03.001","article-title":"Estrogen decline is a risk factor for paclitaxel-induced peripheral neuropathy: clinical evidence supported by a preclinical study","volume":"146","author":"Miyamoto","year":"2021","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2022.01.006_bib9","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2014.58.8533","article-title":"Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (alliance)","volume":"33","author":"Pachman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jphs.2022.01.006_bib10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/cncr.27732","article-title":"Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer","volume":"119","author":"Argyriou","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jphs.2022.01.006_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12974-019-1581-6","article-title":"Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin\/thrombomodulin system in rodents: negative impact of anticoagulants","volume":"16","author":"Tsubota","year":"2019","journal-title":"J\u00a0Neuroinflammation"},{"key":"10.1016\/j.jphs.2022.01.006_bib12","doi-asserted-by":"crossref","first-page":"173196","DOI":"10.1016\/j.ejphar.2020.173196","article-title":"Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity","volume":"880","author":"Minami","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jphs.2022.01.006_bib13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00280-020-04135-8","article-title":"A\u00a0placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy","volume":"86","author":"Kotaka","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jphs.2022.01.006_bib14","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.bbadis.2014.06.017","article-title":"Involvement of the nuclear high mobility group B1 peptides released from injured hepatocytes in murine hepatic fibrogenesis","volume":"1842","author":"Kao","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jphs.2022.01.006_bib15","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/hep.30093","article-title":"High mobility group box-1 drives fibrosis progression signaling via the receptor for advanced glycation end products in mice","volume":"68","author":"Ge","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jphs.2022.01.006_bib16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","article-title":"Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer","volume":"15","author":"Rubbia-Brandt","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jphs.2022.01.006_bib17","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","article-title":"Risk factors for development of and progression of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"25","author":"Corbacioglu","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jphs.2022.01.006_bib18","doi-asserted-by":"crossref","first-page":"152882","DOI":"10.1016\/j.tox.2021.152882","article-title":"Oxaliplatin-induced hepatic sinusoidal obstruction syndrome","volume":"460","author":"Zhu","year":"2021","journal-title":"Toxicology"},{"key":"10.1016\/j.jphs.2022.01.006_bib19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jphs.2022.01.006_bib20","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jphs.2022.01.006_bib21","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hep.22429","article-title":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes","volume":"48","author":"Fracanzani","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jphs.2022.01.006_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum alanine aminotransferase levels","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jphs.2022.01.006_bib23","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jphs.2022.01.006_bib24","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1096\/fj.07-8770com","article-title":"Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats","volume":"21","author":"Liu","year":"2007","journal-title":"Faseb J"},{"key":"10.1016\/j.jphs.2022.01.006_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuropharm.2018.08.040","article-title":"Paclitaxel-induced HMGB1 release from macrophages and its implication for peripheral neuropathy in mice: evidence for a neuroimmune crosstalk","volume":"141","author":"Sekiguchi","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jphs.2022.01.006_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J\u00a0Neurosci Methods"},{"key":"10.1016\/j.jphs.2022.01.006_bib27","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.bbadis.2018.08.037","article-title":"Animal models of drug-induced liver injury","volume":"1865","author":"McGill","year":"2019","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"key":"10.1016\/j.jphs.2022.01.006_bib28","first-page":"43","article-title":"Mouse models of liver fibrosis","volume":"45","author":"Weiler-Normann","year":"2007","journal-title":"Z\u00a0Gastroenterol"},{"key":"10.1016\/j.jphs.2022.01.006_bib29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.intimp.2015.02.018","article-title":"5-Aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside alleviated carbon tetrachloride-induced acute hepatitis in mice","volume":"25","author":"Yang","year":"2015","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.jphs.2022.01.006_bib30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.fct.2016.10.025","article-title":"Reversal of ethanol-induced hepatotoxicity by cinnamic and syringic acids in mice","volume":"98","author":"Yan","year":"2016","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.jphs.2022.01.006_bib31","article-title":"Thrombocytopenia and hemostatic changes in acute and chronic liver disease: pathophysiology, clinical and laboratory features, and management","volume":"10","author":"Scharf","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jphs.2022.01.006_bib32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/jat\/32.2.140","article-title":"Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration","volume":"32","author":"Esteban-Fernandez","year":"2008","journal-title":"J\u00a0Anal Toxicol"},{"key":"10.1016\/j.jphs.2022.01.006_bib33","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/SLA.0b013e3181c79403","article-title":"Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome","volume":"251","author":"Soubrane","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.jphs.2022.01.006_bib34","doi-asserted-by":"crossref","first-page":"e2454","DOI":"10.1097\/MD.0000000000002454","article-title":"Changes in noninvasive liver fibrosis indices and spleen size during chemotherapy: potential markers for oxaliplatin-induced sinusoidal obstruction syndrome","volume":"95","author":"Park","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jphs.2022.01.006_bib35","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0b013e31815774de","article-title":"Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy","volume":"247","author":"Nakano","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.jphs.2022.01.006_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106485","article-title":"Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy","volume":"9","author":"Kelley","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2022.01.006_bib37","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1002\/cncr.33108","article-title":"Chemotherapy-induced peripheral neuropathy: identifying the research gaps and associated changes to clinical trial design","volume":"126","author":"St Germain","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jphs.2022.01.006_bib38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s002800050024","article-title":"Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function","volume":"45","author":"Massari","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jphs.2022.01.006_bib39","first-page":"28","article-title":"Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites","volume":"23","author":"Kochi","year":"2011","journal-title":"J\u00a0Chemother"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861322000068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861322000068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:13:40Z","timestamp":1778800420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861322000068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1347861322000068"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2022.01.006","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2022.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}